Origins and immunopathogenesis of autoimmune central nervous system disorders

The field of autoimmune neurology is rapidly evolving, and recent discoveries have advanced our understanding of disease aetiologies. In this article, we review the key pathogenic mechanisms underlying the development of CNS autoimmunity. First, we review non-modifiable risk factors, such as age, sex and ethnicity, as well as genetic factors such as monogenic variants, common variants in vulnerability genes and emerging HLA associations. Second, we highlight how interactions between environmental factors and epigenetics can modify disease onset and severity. Third, we review possible disease mechanisms underlying triggers that are associated with the loss of immune tolerance with consequent recognition of self-antigens; these triggers include infections, tumours and immune-checkpoint inhibitor therapies. Fourth, we outline how advances in our understanding of the anatomy of lymphatic drainage and neuroimmune interfaces are challenging long-held notions of CNS immune privilege, with direct relevance to CNS autoimmunity, and how disruption of B cell and T cell tolerance and the passage of immune cells between the peripheral and intrathecal compartments have key roles in initiating disease activity. Last, we consider novel therapeutic approaches based on our knowledge of the immunopathogenesis of autoimmune CNS disorders. This article reviews key pathogenic mechanisms underlying the development of CNS autoimmunity, focusing on the role of autoantibodies that target neuronal and/or glial cell-surface antigens. The authors consider novel therapeutic approaches based on knowledge of the immunopathogenesis of autoimmune CNS disorders.

Automated summary

This article reviews the key pathogenic mechanisms underlying the development of autoimmune diseases in the central nervous system, including non-modifiable risk factors, interactions between environmental factors and epigenetics, disease mechanisms associated with the loss of immune tolerance, the role of neuroimmune interfaces, and novel therapeutic approaches based on the immunopathogenesis.